Imidapril Qualigen

Imidapril, the active ingredient in Imidapril Qualigen, is an ACE inhibitor presented as an oral dosage form for oral use. It is employed to treat hypertension and may be prescribed for patients with certain forms of heart failure.

GNH USA supplies Imidapril Qualigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU quality standards and is manufactured under strict GMP conditions.

Imidapril is an ACE inhibitor that acts on the renin‑angiotensin system to manage conditions related to high blood pressure. Hypertension: Reduces systolic and diastolic blood pressure, decreasing cardiovascular risk. Chronic heart failure: Improves ventricular function and reduces symptoms of fluid overload. Post‑myocardial infarction left ventricular dysfunction: Helps prevent adverse remodeling and supports cardiac recovery.

Imidapril may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Cough: dry, persistent throat irritation. - Dizziness or light‑headedness: especially after first doses. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness. - Hypotension: especially in volume‑depleted patients. - Taste disturbances: altered or metallic taste.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue or airway. - Severe hypotension: marked drop in blood pressure leading to fainting. - Neutropenia: significant reduction in white blood cells. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Renal impairment: worsening kidney function. - Anaphylactic reactions: systemic allergic response.

When prescribing Imidapril, clinicians should consider several safety measures to minimize risks. Monitor blood pressure: check regularly during initiation and dose adjustments. Assess renal function: evaluate serum creatinine and eGFR before and during therapy. Check electrolytes: especially potassium levels to avoid hyperkalaemia. Avoid use in pregnancy: contraindicated due to potential fetal harm. Caution in elderly: start with lower dose and monitor for hypotension. Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Imidapril can interact with other medicines, altering its effectiveness or increasing adverse effects.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use may increase risk of renal impairment. - Potassium‑sparing diuretics (e.g., spironolactone): may cause hyperkalaemia. - NSAIDs (e.g., ibuprofen): can reduce antihypertensive effect and impair renal function. - Lithium: increased lithium levels leading to toxicity. - Dual ACE inhibitor/ARB therapy: heightened risk of hypotension and renal dysfunction.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance hypotensive effect. - Beta‑blockers: additive blood pressure lowering. - Calcium channel blockers: possible increased incidence of cough. - Rifampin: may reduce plasma concentration of Imidapril. - Antidiabetic agents: monitor blood glucose as ACE inhibitors can affect glycemic control.